Second stem cell transplant shows promise for returning myeloma
NCT ID NCT01009840
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, busulfan and bortezomib, given before a second stem cell transplant in 30 patients with multiple myeloma that had returned after a previous transplant. The goal was to see if this approach could control the disease. Results showed that many patients had a reduction in cancer levels six months after the transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
busulfan and bortezomib
What this could lead to
If successful, this approach could offer a treatment option for patients with multiple myeloma that has returned after a first stem cell transplant.
What could go wrong
This is a small, early-phase study with only 30 participants. The results may not apply to all patients, and the treatment carries risks like infection and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Arizona Cancer Center
Tucson, Arizona, 85724, United States
-
Blood and Marrow Transplant Group of Georgia
Atlanta, Georgia, 30342, United States
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Loyola University Medical Center
Maywood, Illinois, 60153, United States
-
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, B3H 2Y9, Canada
-
South Texas Veterans Health Care System
San Antonio, Texas, 78229, United States
-
Texas Transplant Physician Group, PLLC
San Antonio, Texas, 78229, United States
-
The Western Pennsylvania Hospital
Pittsburgh, Pennsylvania, 15224, United States
-
University of Maryland School of Medicine - Marlene & Stewart Greenebaum Cancer Center
Baltimore, Maryland, 21201, United States
-
University of Pennsylvania -Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States